Compositions targeting prostate-specific membrane antigen (PSMA) and methods for making and using the same
NZ836540APending Publication Date: 2026-09-25AMUNIX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- NZ836540
- Authority / Receiving Office
- NZ · NZ
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-28
- Filing Date
- 2024-02-09
- Publication Date
- 2026-09-25
Smart Images
Figure 1_ABST
Abstract
Provided herein are, inter alia, antigen-binding molecules with binding specificity to cluster of differentiation 3 T cell receptor (CD3), antigen-binding molecules with binding specificity to prostate-specific membrane antigen (PSMA), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.
Need to check novelty before this filing date? Find Prior Art